Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.49 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.49 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.49 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.49 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.49 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.49 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.40 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.40 |
| ▸ | CCR5 known ✓ | P51681 | 1/20 | 0.39 |
| ▸ | PDE5A known ✓ | O76074 | 1/20 | 0.39 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.38 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680046 | 0.98 | KDM4E (0.50) | KDM4ETSHRLMNACYP3A4ESR1 | |
| SCHEMBL29721865 | 0.98 | KDM4E (0.50) | KDM4ETSHRLMNACYP3A4ESR1 | |
| SCHEMBL11122315 | 0.96 | KDM4E (0.49) | KDM4ETSHRLMNACYP3A4ESR1 | |
| Dimethylamine SCHEMBL3686153 | 0.92 | KDM4E (0.46) | KDM4ETSHRLMNACYP3A4ESR1 | |
| Formic Acid SCHEMBL28236591 | 0.91 | KDM4E (0.45) | KDM4ETSHRLMNACYP3A4ESR1 | |
| Maleic Acid SCHEMBL27920212 | 0.88 | KDM4E (0.44) | KDM4ETSHRLMNACYP3A4ESR1 | |
| Pyrrole SCHEMBL28102266 | 0.88 | TSHR (0.43) | KDM4ETSHRLMNACYP3A4ESR1 | |
| SCHEMBL9685375 | 0.85 | KDM4E (0.41) | KDM4ETSHRLMNACYP3A4ESR1 | |
| SCHEMBL3328912 | 0.81 | KDM4E (0.44) | KDM4ETSHRLMNACYP3A4ESR1 | |
| SCHEMBL11865903 | 0.81 | CES2 (0.46) | KDM4ETSHRLMNAHIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105218436-B | A method of preparing 4- Chloro-2-Pyridyle methyl formate | 济南诚汇双达化工有限公司 | 2019-02-05 | — | — | CN | claimed |
| CN-105218436-A | A kind of method preparing 4-Chloro-2-Pyridyle methyl-formiate | JINAN CHENGHUI SHUANGDA CHEMICAL CO LTD | 2016-01-06 | — | — | CN | claimed |
| CN-105218436-B | A method of preparing 4- Chloro-2-Pyridyle methyl formate | 济南诚汇双达化工有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-105218436-B | A method of preparing 4- Chloro-2-Pyridyle methyl formate | 济南诚汇双达化工有限公司 | 2019-02-05 | — | — | CN | disclosed |
| EP-3156049-A1 | PHARMACEUTICAL COMPOSITION OF PRASUGREL | Alembic Pharmaceuticals Limited (IN) | 2017-04-19 | — | — | EP | disclosed |
| CN-105246893-A | Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2) | SANOFI SA | 2016-01-13 | — | — | CN | disclosed |
| CN-105218436-A | A kind of method preparing 4-Chloro-2-Pyridyle methyl-formiate | JINAN CHENGHUI SHUANGDA CHEMICAL CO LTD | 2016-01-06 | — | — | CN | disclosed |
| CN-105218436-A | A kind of method preparing 4-Chloro-2-Pyridyle methyl-formiate | JINAN CHENGHUI SHUANGDA CHEMICAL CO LTD | 2016-01-06 | — | — | CN | disclosed |
| EP-2625170-A1 | 1,4-OXAZEPANE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2013-08-14 | — | — | EP | disclosed |
| CN-103102355-A | Tetrahydrothienopyridine compound with optical activity | DING KE | 2013-05-15 | — | — | CN | disclosed |
| WO-2012046882-A1 | 1,4-OXAZEPANE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | WO | disclosed |
| US-6737416-B2 | THROMBOLYTIC AGENT HAVING HIGHER SAFETY | MEIJI SEIKA KAISHA LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| US-20030119787-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | MEIJI SEIKA KAISHA LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| US-6576627-B1 | Such as 7-amino-2-((2-methyl-1-(3-phenylpropanoylamino)-propyl)hydroxyphosphinoyl) -methylheptanoic acid; thrombotic disease | MEIJI SEIKA KAISHA LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| EP-1152004-B1 | Phosphonic acid derivatives having carboxypeptidase B inhibitory action | MEIJI SEIKA KAISHA (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-1174434-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | MEIJI SEIKA KAISHA LTD. (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1152004-A1 | PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY | MEIJI SEIKA KAISHA LTD. (JP) | 2001-11-07 | — | — | EP | disclosed |
| JP-2000351792-A | FIFTEEN-MEMBERED MACROLIDE COMPOUND | TAISHO PHARMACEUT CO LTD | 2000-12-19 | — | — | JP | disclosed |
| CN-1052240-C | Process for preparing inhibitors of postinfective viral proteases | ABBOTT LAB (DE) | 2000-05-10 | — | — | CN | disclosed |
| CN-1050545-A | Inhibitors of post-infective viral proteases | HOECHST AG (DE) | 1991-04-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119787-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | CPB1, RNPEP, CPN1 | ESR1 4259/4885ADRA2A 2928/4885PDE4A 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.